LAD603 treatment for adults with severe to very severe alopecia areata
Official title: A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata
Run by Almirall, S.A. · NCT07311564 · Data updated 2026-11-12
This trial will test whether LAD603 can help adults with severe to very severe alopecia areata regrow scalp hair.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 136 (estimated) |
| Sponsor | Almirall, S.A. Industry-sponsored |
| Locations | 1 site (Omaha, Nebraska) |
| Status | Recruiting |
| Started | December 17, 2025 |
| Main results expected | June 23, 2027 |
| Study ends | November 21, 2027 |
| Registry record updated | May 20, 2026 |
| Trial ID | NCT07311564 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–65 with severe to very severe alopecia areata (≥50% scalp hair loss by SALT) whose current hair-loss episode has lasted at least 6 months but no more than 7 years and who can follow pregnancy-avoidance requirements if applicable.
✕Probably not a fit
Patients with other types of hair loss (for example scarring or traction alopecia), diffuse AA, active inflammatory skin disease, those outside the 18–65 age range, or with episodes shorter than 6 months or longer than 7 years are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 interventional study will administer LAD603 or placebo to adult participants and follow them for hair outcomes and safety. It enrolls adults 18 to 65 with severe to very severe AA (≥50% scalp hair loss by SALT) whose current episode has lasted between 6 months and 7 years. Investigators will monitor scalp hair using SALT, collect safety labs, and measure pharmacokinetics, immunogenicity, and pharmacodynamic biomarkers. The trial is sponsored by Almirall and conducted at an investigator site in Omaha, Nebraska.
Why it matters
Potential benefit: If effective, LAD603 could produce meaningful scalp-hair regrowth and reduce severe hair loss in adults with alopecia areata.
How similar studies have gone: Other systemic agents for severe AA, notably JAK inhibitors, have produced positive results, so the therapeutic approach has precedent, but LAD603 itself is a novel agent still being tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Participant is a male or female between 18 and 65 years old at the time of signing the informed consent.
* Severe to very severe AA criteria:
1. Greater than or equal to (\>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits.
2. Current episode of hair loss lasting at least 6 months and not exceeding 7 years.
* Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,
Exclusion Criteria:
AA, Skin Specific, and Other Inflammatory Diseases
* Participants have other types of alopecia (including but not limited to traction, scarring alopecia).
* Participants with "diffuse" type AA.
* Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.
Other Medical Conditions
* Participant has previous severe adverse reaction to subcutaneously administered medication.
* Participant has any of the following liver safety laboratory results at Screening
1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to (\>=) 2.5 × upper limit of normal (ULN)
2. Total bilirubin (TBL) \>=1.5 × ULN (TBL \>=3 × ULN in participants with Gilbert's syndrome)
3. Alkaline phosphatase (ALP) \>=1.5 × ULN
Prior/Concomitant Therapy
* Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.
Where it's running
-
Investigator Site 1
Omaha, Nebraska, United States Recruiting
Study contacts
- Study coordinator: Davide Carluccio
- Email: gco@almirall.com
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?
This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.
-
Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata
This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.
-
VC005 tablets in teens with severe alopecia areata
This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.
-
VC005 tablets in severe alopecia areata
This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.
-
Ritlecitinib for patchy hair loss in teens and adults with alopecia areata
This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.
-
Alopecia Areata: looking at ferroptosis markers in blood
This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.